<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952793</url>
  </required_header>
  <id_info>
    <org_study_id>2018/63</org_study_id>
    <nct_id>NCT03952793</nct_id>
  </id_info>
  <brief_title>Organoids From Metastases of Prostate Cancer</brief_title>
  <acronym>OrMePro</acronym>
  <official_title>Development of the Organoids Technique From Metastases From Patients With Advanced Form of Prostate Cancer: Use in Basic Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Méditerranéen de Médecine Moléculaire UMR_S-1065</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is the development of the organoid culture technique from metastases
      from patients with advanced form of prostate cancer. Once the technique is set up, the
      organoid will serve to test several antitumor molecules.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">December 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of establishment of the organoid culture</measure>
    <time_frame>15 days</time_frame>
    <description>The success rate is defined by the rate of successful cell culture. A Cell culture is successful when organoids grow from dividing cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drugs testing on organoid for cell viability</measure>
    <time_frame>20 days</time_frame>
    <description>Viable cell count in different cells culture conditions using Cell titer Glo and viable cell count using typan blue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell Apoptosis Molecular and cellular mechanisms of drugs responses</measure>
    <time_frame>20 days</time_frame>
    <description>Apoptosis biomarkers analysis in microscopy. Caspase 3 will be assess using microspcopy .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell proliferation Molecular and cellular on mechanisms of drugs responses</measure>
    <time_frame>20 days</time_frame>
    <description>Proliferative biomarkers analysis in microscopy. Ki67 will be assess using microspcopy .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>extended biopsy</intervention_name>
    <description>Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with metastatic prostate cancer

          -  Patient having a biopsy programmed as part of his care.

          -  Patient having a biopsy programmed as part of hiscare.

          -  Patient with sufficient tumor volume after imaging data review by the radiologist to
             guarantee a sufficient quantity of material for the diagnosis of biopsy and additional
             material for the study.

          -  INR &lt;1.5; Platelets &gt; 50000 / μL

        Exclusion Criteria:

          -  Patient under age of 18 years.

          -  Patient under Plavix or Effient or Ticlid without possibility of suspension for 5
             days, low molecular weight heparin without possibility of suspension of the dose
             before the intervention, or Fondaparinux without possibility of suspension, or ReoPro
             without possibility of suspension for 24h and aPTT &lt;50s and ACT &lt;150s, or Integrilin
             or Aggrastat or Argatroban without possibility of suspension 4 H before the
             intervention, or Angiomax without possibility of suspending 2H to 3H if CrCL&gt; 50 mL /
             min or 3H to 5h if CrCL &lt;50 mL / min before the intervention or and Pradaxa without
             possibility of suspension 2 to 3 days if CrCL&gt; 50 mL / min or 3 to 5 days if CrCL &lt;50
             mL / min before the procedure

          -  Patient under desmopressin acetate (DDAVP)

          -  Patient with HIV or Hepatitis C positive or Hepatitis B infection, defined by either a
             detection of the HBs antigen or the presence of anti HBc antibodies without HBs
             antibody detectable.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Colin DEBAIGT, PhD</last_name>
    <phone>+33 4 92 03 17 78</phone>
    <email>colin.debaigt@nice.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin DEBAIGT, PhD</last_name>
      <phone>+33 4 92 03 17 78</phone>
      <email>colin.debaigt@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine BORCHIELLINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

